Contemporary Treatment Practices for Subacute Sclerosing Panencephalitis: A Nationwide Survey Among Adult and Pediatric Neurologists in India Authors: Divyani Garg, Archita Makharia, Ayush Agarwal, Ajay Garg, Achal K Srivastava Published: 2024 ABSTRACT Background and Objectives:Subacute sclerosing panencephalitis (SSPE) is a progressive disorder caused due to the persistence of mutant measles virus in the brain. Treatment strategies for SSPE remain largely undefined, and there exists no information on how neurologists are currently managing SSPE.Methods:A survey-based study was conducted among Indian neurologists managing pediatric and adult patients with SSPE. A questionnaire-based survey was circulated by email regarding respondent demographics, preference for disease-modifying strategies, and symptomatic therapy.Results:Survey response was obtained from 298 neurologists (responder rate 9.5%) and eventually analyzed from 266 respondents who managed SSPE in routine practice. This included 222 (83.5%) adult and 44 (16.5%) pediatric neurologists from 21 states of India. Ninety-five respondents (35.7%) indicated that they always advised Isoprinosine (inosine pranobex) to their patients. Regarding interferon therapy, 121 (45.5%) reported never advising it, whereas 56 (21.1%) always advised it. For myoclonus, the most frequently used first-line drug was valproate (181, 68%), followed by levetiracetam (58, 21.8%). Most (150, 56.4%) of the respondents favored personalized therapy for the individual patient in terms of the duration of disease-modifying treatment. The patient follow-up was reported to be poor, with most (171, 64.3%) of the patients following up only occasionally and 24 (9%) respondents indicating that patients are lost to follow-up promptly after the initial visit.Conclusions:While SSPE remains a vaccine-preventable illness and the focus should be on prevention through vaccination, there is an unmet urgent need among Indian neurologists for better-defined treatment strategies for patients with SSPE. Introduction Subacute sclerosing panencephalitis (SSPE) is a neuroinfectious disorder that arises from the persistence of mutant measles virus infection in the brain. India and the adjacent regions of Pakistan, as well as Türkiye and Papua New Guinea remain the hub of SSPE infection, with up to 27.9 cases of SSPE per 100,000 cases of measles.[1] However, with the resurgence of measles in several parts of the world,[23] related mainly to vaccine hesitancy,[4] SSPE is likely to emerge as a global concern. While vaccination for measles virus is well known to reduce the incidence of measles and subsequent SSPE, SSPE cases are known to occur despite complete vaccination,[5] which is possibly related to subclinical measles infection before vaccination. The clinical picture is dominated by myoclonus, neuropsychiatric abnormalities, seizures, visual abnormalities, and movement disorders.[6] In the initial stages, psychiatric abnormalities, myoclonus, and movement disorders represent a significant part of the disease burden.[7] Myoclonus is particularly perturbing, as it leads to recurrent falls,[8] drop attacks, and difficulty in managing activities of daily living. The disease usually has a progressive course, culminating in death within 1–3 years of diagnosis. Treatment strategies for SSPE, which include both disease-modifying strategies and symptom-based therapies, are based on limited evidence[9] and largely remain individualized and experiential to the treating physician.[10] Moreover, there is a lack of guidelines for treatment, further complicating the treatment approach. Although none of the therapies described in the literature are yet approved by Indian regulatory agencies for SSPE, they continue to be widely used off-label by clinicians due to their perceived benefits. There remains a lack of information on how SSPE is currently being managed. Knowledge of current treatment practices is crucial to understand physician preferences, treatment-related challenges, and gaps in treatment. This may inform the initial step to the eventual development of guidelines. In this survey-based analysis, we aimed to describe current treatment strategies for the management of SSPE among Indian neurologists. Methods The study was initiated after obtaining approval from the institutional ethics committee. The Checklist for Reporting Results of Internet E-Surveys was used to report the methodology and results of the survey.[11] Survey questionnaire We designed a self-administered online questionnaire to assess current treatment practices in the management of SSPE, using Google Forms [Supplementary 1]. All respondents had to provide consent to be surveyed at the beginning of the survey. Only those who consented could proceed further. The questionnaire comprised 29 questions. The first six questions collected participant-related details. Seven questions required response on a Likert scale. Any questions that were not responded to were not included in the final analysis. The average time to complete the survey was 5–7 min. Duplicate submissions from the same submitter (assessed using name and email address) were removed. Survey respondents were able to edit their responses during the process of submission, but not after they had submitted the responses. Study population We conducted a closed survey among adult and pediatric neurologists currently practicing in India. The participants could be affiliated with government or private health-care facilities. We excluded responses from respondents if they indicated that they did not see SSPE patients in their practice. Survey dissemination Potential participants were approached via electronic mail. A mailing list of adult and pediatric neurologists was generated from national neurologic scientific societies and various scientific groups. A reminder mail was sent after 1 week and then 2 weeks. No incentives were provided to participants for participating in the survey. Responses were collected over a survey period of 6 weeks (May–June 2024). Statistical analysis The survey responses were initially auto-tabulated into a spreadsheet and then manually cross-checked for errors. Proportions were represented as frequency (percentage). Chi-square/Fisher’s exact test was used for quantitative analysis. A P value of <0.05 (two-tailed) was considered significant. Results The survey was sent out to 3118 neurologists. A total of 298 responses were obtained. The responder rate was 9.5%. The completeness rate for the survey was 100%. Of 298 responses, we included those who indicated that they dealt with patients with SSPE in their routine practice. This included a total of 266 respondents (8.5% of 3118 neurologists) [Table 1]. The survey was answered by 222 (83.5%) adult and 44 (16.5%) pediatric neurologists. These 266 responses were received from 21 states of India [Figure 1], with the maximum number of respondents belonging to Delhi, Tamil Nadu, Maharashtra, West Bengal, and Rajasthan. Of these, 107 (40.25), 117 (43.9%), and 42 (15.8%) respondents belonged to tier 1, 2, and 3 cities/towns, respectively. One hundred and twenty-six (47.4%) respondents were early career neurologists (practicing for 1–5 years), 47 (17.7%) had been practicing for 6–10 years, and 93 (35%) had been practicing for more than 10 years. Most respondents indicated that they routinely saw less than one patient with SSPE per month (213, 80.1%). Map of India demonstrating geographic location of respondents Table 1Summary of survey responses (n=266) related to participant characteristicsCharacteristicsFrequency (%)Respondent characteristics Adult neurologist222 (83.5) Pediatric neurologist44 (16.5)Years of neurology practice 1–5 years126 (47.4) 6–10 years47 (17.7) More than 10 years93 (35)Number of SSPE patients seen Less than one per year92 (34.6) Less than one per month121 (45.5) One to two per month28 (10.5) Three to five per month21 (7.9) More than five per month4 (1.5)SSPE: subacute sclerosing panencephalitis Summary of survey responses (n=266) related to participant characteristics SSPE: subacute sclerosing panencephalitis In terms of treatment strategies, 95 (35.7%) indicated that they always advised Isoprinosine (inosine pranobex) to their patients, while 48 (18%) never advised it [Table 2]. Regarding interferon therapy, 121 (45.5%) reported never advising it, whereas 56 (21.1%) always advised it. Among pediatric neurologists, 14/44 (31.8.%) indicated that they advised interferon, compared to 120/222 (54.1%) adult neurologists (P = 0.007) [Supplementary 2]. Of those who advised interferon (n = 145), most (125, 86.2%) advised interferon alpha, while the rest (20, 13.8%) advised interferon-beta. The route of interferon alpha used was intrathecal alone, advocated by 120 (82.8%) respondents. Other routes used were subcutaneous (8, 5.5%) (interferon-beta), intraventricular alone (8, 5.5%), and combined intrathecal and intraventricular (7, 4.8%). A combination of Isoprinosine and interferon was always used by 34 (12.8%), frequently used by 37 (13.9%), sometimes used by 61 (22.9%), and never used by 134 (50.4%) respondents. No other medications aimed at disease modification were used by the respondents. Table 2Use of disease-modifying therapy in SSPE (n=266)CharacteristicFrequency (%)How frequently do you advise use of Isoprinosine? Always95 (35.7) Frequently60 (22.6) Sometimes63 (23.7) Never48 (18.0)How frequently do you advise use of interferon? Always56 (21.1) Frequently28 (10.5) Sometimes61 (22.9) Never121 (45.5)What preparation of interferon do you use?(n=145)a Interferon alpha125 (86.2) Interferon beta20 (13.8)What route of interferon administration do you employ?(n=145)a Intrathecal alone120 (82.8) Intraventricular alone8 (5.5) Combined intrathecal and intraventricular7 (4.8) Subcutaneous8 (5.5) Intravenous2 (1.4)How frequently do you use a combination of Isoprinosine and interferon? Always34 (12.8) Frequently37 (13.9) Sometimes61 (22.9) Never134 (50.4)How long do you treat patients with disease-modifying treatment? Six months28 (10.5) One year13 (4.9) Lifelong75 (28.2) Individualized approach150 (56.4)aAnswered by only those who used interferon therapy. SSPE: subacute sclerosing panencephalitis Use of disease-modifying therapy in SSPE (n=266) aAnswered by only those who used interferon therapy. SSPE: subacute sclerosing panencephalitis Supplementary 2Differences in responses between adult and pediatric neurologistsCharacteristicAdult neurologists(n=222) n (%)Pediatric neurologists(n=44) n (%) P Use of Isoprinosine182 (81.9)36 (81.8)NSUse of interferon120 (54.1)14 (31.8)0.0070First-line drug for myoclonus Valproate147 (66.2)34 (77.2)NSAntipsychotic agent preferred Quetiapine164 (73.9)2 (4.5)P<0.0001 Risperidone30 (13.5)33 (75)Duration of treatment Lifelong66 (29.7)9 (20.5)NSCost of treatment Less than INR 100016 (7.2)4 (9.1)0.0258 INR 1001–300053 (23.9)12 (27.3) INR 3001–500063 (28.4)18 (40.9) More than INR 500090 (40.5)10 (22.7)NS: not significant Differences in responses between adult and pediatric neurologists NS: not significant In terms of symptom-based therapy, for myoclonus, the most frequently used first-line drugs were valproate (181, 68%), levetiracetam (58, 21.8%), carbamazepine (10, 3.8%), clobazam (5, 1.9%), and clonazepam (10, 3.8%), and nine respondents indicated that they used combinations of the above agents [Table 3]. Second-line agents included levetiracetam, valproate, carbamazepine, clonazepam, and clobazam. For psychosis, most respondents preferred quetiapine (163, 61.3%), followed by risperidone (64, 24.1%), olanzapine (25, 9.4%), and others (haloperidol, clozapine). Risperidone was favored by pediatric neurologists (33, 75%), whereas adult neurologists (30, 13.5%) (P < 0.00001) preferred the use of quetiapine [Supplementary 2]. For associated movement disorders other than myoclonus, 220 (82.7%) respondents used symptomatic therapy to varying extent. Table 3Use of symptom-based treatment in SSPE (n=266)CharacteristicFrequency (%)Preference for first-line drug for myoclonus Valproate181 (68.0) Levetiracetam58 (21.8) Carbamazepine10 (3.8) Clonazepam10 (3.8) Clobazam5 (1.9) Others2 (0.8)Preference for second-line drug for myoclonus Levetiracetam130 (48.8) Clobazam54 (20.3) Valproate44 (16.5) Carbamazepine9 (3.4) Others30 (11.3)Preferred drug for management of psychosis Quetiapine164 (61.7) Risperidone64 (24.1) Olanzapine25 (9.4) Haloperidol10 (3.8) Others3 (1.1)Use of drugs specific for movement disorders related to SSPE Always32 (12.0) Frequently64 (24.1) Sometimes125 (46.9) Never46 (17.3)SSPE: subacute sclerosing panencephalitis Use of symptom-based treatment in SSPE (n=266) SSPE: subacute sclerosing panencephalitis Most of the respondents (213, 80%) repeated electroencephalography (EEG) on follow-up to a varying extent [Table 4]. The time of repeating EEG was also variable. In terms of repeat neuroimaging, 111 (41.7%) indicated that they never repeated magnetic resonance imaging for their patients. The timing of repeat imaging, if done, was variable. While lifelong disease-modifying therapy was advocated by 75 (28.2%) respondents, 150 (56.4%) favored a personalized approach to the individual patient in terms of duration of disease-modifying therapy. In terms of follow-up, most of the respondents (110, 41.4%) advised monthly follow-up. The patient follow-up was reported to be poor. Most respondents (171, 64.3%) indicated that patients followied up occasionally; 24 (9%) respondents indicated that patients became lost to follow-up after the initial visit. Physician reasons for loss to follow-up included disease progression (188, 70.6%), self-referral for second or third opinion (105, 39.5%), financial constraints (101, 38%), and patient death (80, 30.1%). Survey respondents indicated that the average monthly cost of their treatment regimens was above Rs. 5000/- (100, 37.6%), Rs. 3001–Rs. 5000 (81, 30.5%), Rs. 1001–3000 (65, 24.4%), and below Rs. 1000 (20, 7.5%). Respondents’ opinions regarding prominent challenges with treatment of SSPE included poor disease prognosis, lack of effective treatment, cost and availability of drugs, and lack of guidelines for treatment. Specifically, regarding availability, 25/266 (9.4%) indicated lack of availability of drugs, of which 15/266 (5.6%) indicated lack of availability of Isoprinosine. Table 4Follow-up of patients with SSPE (n=266)CharacteristicFrequency (%)How frequently do you repeat EEG during follow-up? Always28 (10.5) Frequently46 (17.3) Sometimes139 (52.3) Never53 (19.9)How long after the initial EEG do you repeat an EEG? One month9 (3.4) Three months70 (26.3) Six months54 (20.3) Never53 (19.9) On an individual basis80 (30.1)How frequently do you repeat neuroimaging during follow-up?6 (2.3) Always5 (1.9) Frequently144 (54.1) Sometimes111 (41.7) Never How long after initial neuroimaging do you repeat it? Three months11 (4.1) Six months32 (12) Never111 (41.7) On an individual basis112 (42.2)How frequently do you advise patients to follow up? Monthly110 (41.4) Once in 2 months37 (13.9) Once in 3 months82 (30.8) Whenever possible24 (9) Others13 (4.9)How frequently do your patients follow-up? Regularly, as prescribed71 (26.7) Poor171 (64.3) Never- loss of follow-up after the first visit24 (9)Reasons for loss to follow-upa Disease progression188 (70.6) Self-referral for another opinion105 (39.5) Financial constraints101 (38) Death80 (30.1) Others14 ((5.3)Average monthly cost of treatment Less than INR 100020 (7.5) INR 1001-300065 (24.4) INR 3001-500081 (30.5) Above INR 5000100 (37.6)aMore than one response allowed. EEG: electroencephalography, SSPE: subacute sclerosing panencephalitis Follow-up of patients with SSPE (n=266) aMore than one response allowed. EEG: electroencephalography, SSPE: subacute sclerosing panencephalitis Discussion We assessed contemporary treatment practices among adult and pediatric Indian neurologists while managing patients with SSPE through a survey-based study. The respondents represented a realistic balance of adult and pediatric practicing neurologists from different regions of the country. It yielded key insights into current trends in the treatment of SSPE in India. While scientific evidence remains limited on this theme, an understanding of contemporary treatment practices is required to identify critical gaps, challenges, and future research avenues. A large array of agents has been tried in SSPE, including interferon alpha/-beta, Isoprinosine, lamivudine, ribavirin, favipiravir, aprepitant, and ketogenic diet. Modest effects have been noted for interferon alpha and Isoprinosine, with stabilization reported in 44%–55% of patients.[1213] Immune therapy has also been attempted, including intravenous immunoglobulins (IVIg), rituximab, steroids, plasma exchange, and even stem cell transplantation, but without great success.[9] The survey reflected this, with maximum respondents indicating the usage of interferons and/or Isoprinosine. Immune therapy (IVIg) was used for some in the case of fulminant SSPE. From the survey response, it was observed that many respondents used a combination of interferon alpha and Isoprinosine. Interestingly, in a single randomized trial that compared the efficacy of Isoprinosine therapy alone to a combination of Isoprinosine plus intraventricular interferon alpha, no difference was observed between these two groups in the primary efficacy end points at the end of 6 months.[12] The current practice raises concerns about whether combinational therapy given for longer periods of time may yield better results compared to single therapy. In an older small study among 22 patients, it was found that there was eventual deterioration despite combinational therapy.[14] Whether higher doses or different regimens may be more effective is not clear. Interestingly, there has been no trial of interferon alpha alone versus combinational therapy. Although intrathecal was the most commonly used route for interferon alpha, it remains unclear which is the best route for administration of interferon alpha therapy, with intraventricular (via Ommaya reservoir),[1215] lumbar infusion,[161718] and repeated intrathecal dosage being described in the literature. The duration of therapy advocated seemed variable, although long-term and even lifelong therapy is suggested by previous expert reviews.[1] Whether long-term disease-modifying therapy is associated with prolonged survival remains to be determined, although we have personally experienced very long-term stabilization in at least a few patients maintained on long-term interferon therapy (personal observation). However, long-term therapy in patients with SSPE is fraught with challenges, as treatment remains expensive and/or invasive, as in the case of interferon therapy. The availability of these drugs has also been an issue in India, intermittently. A striking and concerning issue was the loss to follow-up among patients. This may be related to the disease (which has a grave prognosis and is progressive), treatment related (lack of effective treatment, high cost, and lack of widespread availability), physician related (nihilistic attitude, referral to other centers), and patient related (caregiver fatigue, transition to alternate therapies, loss of hope). However, these considerations merit an in-depth analysis in future studies. We found an interesting difference among treatment strategies employed by adult and pediatric neurologists. Most strikingly, pediatric neurologists preferred to use Isoprinosine and none indicated the use of interferon therapy, whereas many adult neurologists were using interferon therapy. This may be due to the injectable or invasive approach that interferon therapy entails, which may be challenging in the pediatric population. Pediatric neurologists also preferred the use of risperidone for psychotic symptoms, perhaps due to wide availability. Myoclonus was managed using antiseizure medications, chiefly valproate, levetiracetam, and clonazepam. Myoclonus is a characteristic feature in SSPE. However, the efficacy of these agents in managing the myoclonus of SSPE has not been established in objective trials, although anecdotal data suggests moderate to excellent efficacy. In the survey, carbamazepine remained less preferred by respondents. There is some evidence that carbamazepine is effective for the myoclonus of SSPE,[19] contrary to its aggravating effects on idiopathic generalized epilepsy syndromes. The survey was strengthened by wide national representation and a 100% survey completion rate. We were able to capture data from adult and pediatric neurologists and understand differential aspects of treatment in these two groups. The survey was limited by a low responder rate, particularly among pediatric neurologists, and overall, it represented a small fraction of Indian neurologists. Considering a database of 3500 neurologists, the margin of error was 5% for 298 responses, but was 6% for 266 responses. However, this is a limitation of survey-based studies. Moreover, we further excluded those respondents from the analysis who did not manage SSPE patients routinely, thereby increasing the strength of the responses. We sent the survey only by email registered with national societies, and several of these were nonoperational, which contributed to a reduced number of successful email invitations. Another limitation was the use of Likert scale for several themes that used qualitative variables, which was used due to potentially heterogeneous responses to these themes. The Likert scale, however, is a well-established method of gathering and analyzing information.[20] The survey has uncovered several concerns, which also pave the way for future research endeavors in SSPE treatment. A sense of therapeutic nihilism prevailed among survey respondents, emanating from a lack of effective curative therapy. This underscores the urgent need to develop and evaluate treatment strategies for the management of SSPE. While interferon alpha and Isoprinosine were both available in India at the time of conducting this survey, controlled trials on these therapies and on the efficacy of their comparative and/or combinational use remain unavailable. Another gap perceived by respondents was the lack of guidelines for treatment. National stakeholders, including patients, advocacy forums, physicians, and scientific bodies, must develop guidelines for the treatment of SSPE to better delineate a paradigm for management, based on the best available evidence. While it remains certain that vaccination is the best strategy to tackle the burden of SSPE, there is a continued need to understand how to manage patients who do become afflicted with the disease. Conflicts of interest There are no conflicts of interest. Supplementary 1: Google Form used for data entry for the survey Contemporary treatment practices in the management of Subacute Sclerosing Panencephalitis in India You are invited to participate in a research survey aimed at adult and pediatric neurologists that seeks to understand practice protocols for managing patients with Subacute Sclerosing Panencephalitis (SSPE) in our setting. Participation involves completing an online survey, which is estimated to take five minutes. The results of this study may be published, but individual responses will remain confidential. * indicates required Question 1. Email * ____________________________________ 2. By clicking on the “I Agree” button below, you acknowledge that you have read * and understood this consent form, and you agree to participate in this research survey. Mark only one oval. I Agree I do not agree Survey questionnaire 3. Please enter your hospital/ clinic name: * ____________________________________ 4. Please enter the city/town where you are working: * ____________________________________ 5. Please enter your designation: * Mark only one oval. Adult Neurologist Pediatric Neurologist 6. Please indicate how many years you have been practicing post-neurology * training: Mark only one oval. 0-5 years 6-10 years More than 10 years 7. Please indicate whether you see patients with SSPE in your routine practice? * Mark only one oval. Yes No 8. How many patients with SSPE do you see in your routine practice? * Mark only one oval. More than 5 per month 3-5 per month 1-2 per month Less than 1 per month Less than 1 per year Other:___________________ 9. How frequently do you advise Isoprinosine to your patients with SSPE? * Mark only one oval. Always Frequently Sometimes Never 10. How frequently do you advise Interferon to your patients with SSPE? * Mark only one oval. Always Frequently Sometimes Never 11. What preparation of Interferon do you use in your patients with SSPE? * Mark only one oval. Interferon Alpha Interferon beta I do not use Interferon for SSPE 12. When treating patients with SSPE using interferon, which route of administration do you most commonly employ? * Mark only one oval. Subcutaneous Intravenous Intrathecal Intraventricular Combined Intrathecal and Intravenous I do not use interferon for SSPE 13. How frequently do you advise a combination of Isoprinosine and interferon to your patients with SSPE? * Mark only one oval. Always Frequently Sometimes Never 14. What is your preference for first line drug for management of myoclonus in SSPE? * Mark only one oval. Levetiracetam Valproate Clobazam Carbamazepine Others 15. If others, please specify ____________________________________ 16. What is your preference for second line drug for management of myoclonus in SSPE? * Mark only one oval. Levetiracteam Valproate Clobazam Carbamazepine Others 17. if others, please specify ____________________________________ 18. What is your first line drug for management of psychiatric (psychotic) symptoms in patients with SSPE? * Mark only one oval. Quetiapine Risperidone Olanzapine Haloperidol Others 19. If others, please specify ____________________________________ 20. How frequently do you advise follow up in your patients with SSPE? * Mark only one oval. Monthly Once in two months Once in three months Whenever possible Others 21. Do you see movement disorders in patients with SSPE? * Mark only one oval. Frequently Sometimes Rarely Never 22. Do you manage movement disorders with drugs specific to movement disorders (for example, tetrabenazine) in your patients with SSPE? * Mark only one oval. Always Frequently Sometimes Never 23. Do you routinely repeat EEG in your patients with SSPE during follow-up? * Mark only one oval. Always Frequently Sometimes Never 24. If you do repeat EEG, how long after the initial EEG do you repeat it? * Mark only one oval. One month Three months Six months I do not repeat EEG in SSPE patients On an individual basis 25. Do you routinely repeat neuroimaging in your patients with SSPE during follow-up? * Mark only one oval. Always Frequently Sometimes Never 26. If you do repeat neuroimaging, how long after the initial imaging do you repeat it? * Mark only one oval. One month Three months Six months I do not repeat imaging On an individual basis 27. How frequently do your patients with SSPE follow up? * Mark only one oval. Regularly as prescribed by me Poor follow up, they come back occasionally Never- they get lost to follow up after the first visit 28. Why do you think patients with SSPE may get lost to follow up after the initial * visits? Check all that apply. □ Financial constraints □ Disease progression □ Death □ They self-refer for second or third opinion □ Other:____________________ 29. How long do you usually treat SSPE with interferons or isoprinosine or other disease-modifying agents? * Mark only one oval. Six months One year Lifelong Individualized approach 30. What is the average monthly cost of treatment for your patients with SSPE? * Mark only one oval. Less than INR 1000/- per month INR 1001-3000 per month/- INR 3001-5000 per month/- >INR 5000 per month 31. What is the main problem with treatment of SSPE, in your opinion? Please describe. * ____________________________________________________________________ ____________________________________________________________________ ____________________________________________________________________ ____________________________________________________________________ ____________________________________________________________________ This content is neither created nor endorsed by Google. Google Forms